Clarius Wins FDA Clearance for AI Cardiac Ultrasound Tool
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
VANCOUVER, British Columbia, June 2, 2026 Clarius Mobile Health has achieved a significant regulatory milestone with the U.S. Food...
CHARLOTTESVILLE, Va., May 7, 2026 RIVANNA announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...
VANCOUVER, BC, Dec. 17, 2025 — Clarius Mobile Health, a global leader in AI-powered handheld ultrasound technology, reported a...
